🔗 Share this article

As the US continues making historic adjustments to its immunization recommendations, a particular individual has surfaced unexpectedly: Tracy Beth Høeg, a US-based physician and public health researcher who first made her name by questioning Covid vaccines during the global health crisis and has concentrated on alleged fatalities after COVID-19 vaccination in her short position at the Food and Drug Administration.

Planned Overhauls to Pediatric Vaccine Program

Agency leaders planned to unveil sweeping changes to the pediatric vaccine schedule in December, bringing the US with Denmark’s immunization schedule, it is understood – a major change that would put the US out of step with much of the world with insufficient data for benefit. This reveal has been postponed until the new year.

Instead of the director of the vaccine center, Høeg is scheduled to speak at the gathering. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this calendar year.

Consolidating Power at the FDA

The acting appointment could signify a closer partnership between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad solidify control at the FDA – and it signals a greater focus upon dismantling already-approved vaccines at the FDA.

Høeg has repeatedly called for ending some childhood shot schedules in the US so as to align more in line with Denmark, a country with universal health coverage and a citizenry approximately the population of the state of Wisconsin.

To date public appearances, she has continued to focus on vaccines – typically the responsibility of Dr. Prasad, director of the FDA’s CBER – as opposed to medication approval.

Questions Over Qualifications

Dr. Høeg has no apparent track record in medication creation, approval processes or administrative roles, which has been typical for previous directors of the CBER. She has served at the FDA as a key advisor to the FDA chief and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for leading the pharmaceutical oversight division, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in managing a sizeable institution. She lacks background in drug approvals.”

Former heads of CBER would “grasp legal statutes and the underlying principles of medication creation”, said a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that prior appointees who headed the center have had.”

This division has an enormous range of responsibilities at the FDA, Woodcock emphasized.

“Everybody just pays attention on the new drug program, but the generic program authorizes a multitude of generic medications. There is also a biosimilars division, non-prescription drug unit and other areas, and every single one need to be supervised,” Dr. Woodcock noted. “The area you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Furthermore, a substantial leadership aspect to the job, which supervises in excess of 5,000 personnel. “It’s a massive leadership role, if you do it right,” the former official concluded.

Official Statement and Disputed Policies

In response to concerns about Dr. Høeg's fitness for the role and whether this appointment represents more teamwork among FDA leaders on vaccines, a representative responded that the “concerns stem from flawed premises”.

“Her resume aligns with the duties of her position,” the representative stated, pointing to the months Dr. Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg assumes responsibility for the commissioner’s new priority voucher program, a disputed one-day therapy clearance system that apparently worried her preceding directors. “By what process are these therapies being chosen for this expedited pathway? Who takes the choices?” Howard questioned. “There is a lot of confidentiality going on at the FDA right now.”

Broadly speaking, he stated, “the Food and Drug Administration seems to be moving towards less stringent rules of pharmaceuticals, aside from vaccines.”

Documented Past Work on Vaccines

Regarding vaccines, Høeg has a more established, if problematic, track record, Howard observe. She authored a study using non-validated crowd-sourced reports to determine the incidence of heart inflammation following COVID-19 immunization. She counseled the Florida top health official Joseph Ladapo, who allegedly have modified findings to indicate COVID-19 vaccinations are riskier than they are.

Part of her “desired changes” for the new government featured revising guidelines for new vaccines and ending “unnecessary” vaccines, she said post-election on a podcast. At the FDA, Dr. Høeg has according to sources floated the idea of excluding teenage boys from obtaining Covid vaccinations.

“She’s an all-around dogmatist who starts off with her conclusions and works backwards to fit the evidence in a highly deceptive, dishonest way,” Dr. Howard argued.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg became part of fellow skeptics, {like|